Zacks Small Cap Research on MSN3h
LGVN Well Positioned for Critical 2025LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) is a company that should be getting more attention from investors and the just released annual results again proved that point. LGVN ...
Hosted on MSN5h
LGND: First Steps into Cell & Gene TherapyLGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported 2024 financial and operational ...
As of December 31, 2024, PMV Pharma had $183.3 million in cash, cash equivalents, and marketable securities, compared to $228.6 million at December 31, 2023. Net cash used in operations was $51.3 ...
Q4 2024 Earnings Call Transcript February 28, 2025 Longeveron Inc. beats earnings expectations. Reported EPS is $1.16, ...
Q4 2024 Earnings Call Transcript February 28, 2025 Operator: Good afternoon, everyone. Welcome to the Crinetics ...
Q2 2025 Earnings Call Transcript February 28, 2025 Silviu Itescu: Good morning, everybody. I’m Silviu Itescu. I’m the Chief ...
LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line ...
FDA has provided input on key elements of the SER-155 allo-HSCT clinical development plans including support for the proposed primary efficacy endpoint of reduction in bloodstream infections (BSIs) as ...
BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has commended Nanomerics for the successful completion of a human ...
Semler expects a decision regarding its QuantaFlo clearance. Click here to read more about SMLR stock and why it is a Hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback